Loading
Life sciences · Journal article
Frontiers in Molecular Biosciences · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Peroxiredoxins (PRDXs) are thiol-specific antioxidant enzymes that maintain cellular redox balance and regulate signaling pathways. They participate in the development of cancer, neurodegenerative disorders, cardiovascular diseases, inflammatory conditions, and infectious diseases. In cancer, PRDXs are frequently overexpressed and promote tumor progression, metastasis, and treatment resistance through interactions with oncogenic pathways. In neurodegenerative and cardiovascular diseases, by contrast, they support cell survival by limiting oxidative damage. Therapeutic strategies directed at PRDXs include small-molecule inhibitors, activators, and gene therapy. PRDX inhibitors sensitize tumor cells to oxidative damage, whereas PRDX activators confer neuroprotection; the principal obstacles are achieving isoform specificity and limiting off-target effects. Here we review the structure and biology of the PRDX family, its isoform- and context-dependent functions across these disease settings, and the evidence supporting PRDXs as therapeutic targets and prognostic biomarkers.